Get the Daily Brief
Latest Biotech News
Inhibrx posts phase II win in rare chondrosarcoma — BLA filing eyed
Inhibrx reported that ozekibart (INBRX‑109), its monoclonal antibody, met the primary endpoint in a registrational Phase II trial for unresectable or metastatic chondrosarcoma, delivering a...
Biophysics maps LNP shapes — route to tissue‑targeted RNA delivery
A multidisciplinary team delineated the detailed shapes and structural heterogeneity of lipid nanoparticles (LNPs) used for RNA delivery, linking particle architecture to delivery performance....
Biogen pays $70M upfront for Vanqua C5aR1 – up to $1B more
Biogen signed an exclusive worldwide license with Vanqua Bio, paying $70 million up front for preclinical C5aR1 antagonist VQ-201 and agreeing to as much as $990 million in milestone payments....
Lilly buys Adverum for eye-gene therapy assets – contingent-value rights included
Eli Lilly agreed to acquire Adverum Biotechnologies to secure ixo-vec, an intravitreal AAV gene therapy in a Phase 3 study for wet age-related macular degeneration. The transaction pays Adverum...
FDA clears GSK’s Blenrep in limited multiple myeloma use – mixed ruling
The U.S. Food and Drug Administration approved GSK’s antibody–drug conjugate Blenrep for a narrowed multiple myeloma indication after a complex regulatory review. The agency cleared Blenrep for...
Ventyx’s NLRP3 inhibitor slashes inflammation marker 78% in Phase 2 – shares surge
Ventyx Biosciences reported Phase 2 data showing oral NLRP3 inhibitor VTX3232 produced rapid and large reductions in high-sensitivity C-reactive protein (hsCRP), with a 78% decline versus placebo...
Tango to move PRMT5 inhibitor into Phase 3 for MTAP‑deleted pancreatic cancer – $225M raise
Tango Therapeutics announced it will launch a pivotal Phase 3 study of vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor designed to exploit MTAP-deleted tumors, after positive Phase 1/2...
Inhibrx posts phase 2 win in rare bone cancer – FDA filing eyed for 2026
Inhibrx reported positive registrational Phase 2 results for ozekibart (INBRX‑109) in unresectable or metastatic chondrosarcoma, meeting the primary endpoint with a statistically significant...
10x, Roche and Prognosys sue Illumina – nine spatial and single‑cell patents at issue
10x Genomics, Roche Sequencing Solutions and Prognosys Biosciences filed twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell sequencing...
Deep learning accelerates antibiotic discovery – Nature Biotechnology validates AI‑guided screens
A team published in Nature Biotechnology demonstrated that deep‑learning models trained on high‑throughput phenotypic screening data can identify structurally novel antibacterial scaffolds,...
Detailed LNP structures revealed – path to tissue‑specific RNA delivery
Researchers from the University of Pennsylvania and collaborators published biophysical analyses mapping the architecture of lipid nanoparticles (LNPs), revealing distinct shapes and internal...
Retrons repurposed as a new class of genome editors – scalable, self‑priming DNA donors
Scientists reported repurposing bacterial retrons to produce intracellular single‑stranded DNA donors for gene editing, identifying candidates from metagenomic sequences and validating activity...
Biogen bets on C5aR1: $70m upfront to Vanqua, $990m more possible
Biogen struck an exclusive global licensing deal for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and agreeing to nearly $1 billion in downstream milestones. The...
Lilly swoops on Adverum: gene therapy buy as cash runs dry
Eli Lilly agreed to acquire Adverum in a deal aimed at securing the biotech’s phase‑3 intravitreal gene therapy ixo‑vec for wet age‑related macular degeneration. Lilly’s offer values Adverum at a...
Two FDA moves on menopause relief: nonhormonal and neurokinin options
The FDA cleared two new therapies for vasomotor symptoms of menopause: elinzanetant, a novel nonhormonal agent, and Bayer’s Lynkuet, described by the company as the first dual neurokinin‑targeted...
Tango’s PRMT5 readout sparks Phase‑3 plan and $225m haul
Tango Therapeutics announced encouraging Phase I/II activity for its MTA‑cooperative PRMT5 inhibitor vopimetostat in MTAP‑deleted pancreatic ductal adenocarcinoma and set a pivotal Phase III start...
Ventyx’s NLRP3 program: swift biomarker cuts ignite buyout chatter
Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced dramatic reductions in inflammatory biomarkers, including a roughly 78% drop in hsCRP versus placebo,...
Moderna’s CMV setback… and a quieter pivot to oncology
Moderna halted development of its cytomegalovirus vaccine mRNA‑1647 after a Phase III study missed the primary efficacy endpoint, delivering results well below company expectations. The failure...
Deep learning accelerates antibiotic discovery: two Nature Biotech papers
Two complementary Nature Biotechnology reports demonstrate deep‑learning models can markedly speed antibacterial discovery by identifying novel scaffolds and prioritizing hits from phenotypic...
Biophysics peels back LNP structure — design rules for delivery
A multidisciplinary team published detailed biophysical analyses linking lipid nanoparticle (LNP) architecture to delivery performance, illustrating that particle shape and internal structure...